Effects of Exercise to Improve Cardiovascular Health

Kelsey Pinckard, Kedryn K. Baskin and Kristin I. Stanford*

Department of Physiology and Cell Biology, Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH, United States

Obesity is a complex disease that affects whole body metabolism and is associated with an increased risk of cardiovascular disease (CVD) and Type 2 diabetes (T2D). Physical exercise results in numerous health benefits and is an important tool to combat obesity and its co-morbidities, including cardiovascular disease. Exercise prevents both the onset and development of cardiovascular disease and is an important therapeutic tool to improve outcomes for patients with cardiovascular disease. Some benefits of exercise include enhanced mitochondrial function, restoration and improvement of vasculature, and the release of myokines from skeletal muscle that preserve or augment cardiovascular function. In this review we will discuss the mechanisms through which exercise promotes cardiovascular health.

Keywords: exercise, obesity—complications, cardiovascular, type 2 diabetes, myokines

INTRODUCTION

Obesity and its associated co-morbidities are increasing at rapid rates across the United States and worldwide (1). Obesity is associated with many adverse health effects, including increased risks of cardiovascular disease (CVD), type 2 diabetes (T2D), certain cancers, and death (2–6). As obesity rates continue to rise, the prevalence of associated comorbidities including T2D and CVD increase concomitantly (7); overweight people are twice as likely, and severely obese people are ten times more likely to develop cardiovascular diseases than individuals of a healthy weight (8).

Regular physical exercise has several beneficial effects on overall health. While decreasing body mass and adiposity are not the primary outcomes of exercise, exercise can mediate several diseases that accompany obesity including T2D and CVD (9–14). Several recent studies have shown that sustained physical activity is associated with decreased markers of inflammation, improved metabolic health, decreased risk of heart failure, and improved overall survival (15–17). Exercise improves overall metabolic health and reduces the development of T2D (18) by improving glucose tolerance (19), insulin sensitivity (20), and decreasing circulating lipid concentrations (21). This occurs primarily through adaptations to the skeletal muscle, liver, and adipose tissue (16, 22, 23).

Physical exercise can also improve cardiovascular function through adaptations to the heart and vascular system (17, 24–27). Regular physical exercise decreases resting heart rate, blood pressure, and atherogenic markers, and increases physiological cardiac hypertrophy (13–15, 28). Exercise improves myocardial perfusion and increases high-density lipoprotein (HDL) cholesterol levels, all of which reduce stress on the heart and improve cardiovascular function in healthy and diseased individuals (11, 15, 29, 30). Given the increasing interest in exercise-based therapies, we will discuss the benefits of exercise on cardiovascular health and the potential mechanisms through which they occur.
CARDOVASCULAR DISEASE

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide (31, 32). Almost half of all adults in the United States have at least one key risk factor for development of CVD (i.e., high blood pressure, high cholesterol, or smoking) (33). CVD encompasses a wide range of conditions that affect the heart and vasculature including arrhythmias, dilated, hypertrophic, or idiopathic cardiomyopathies, heart failure and atherosclerosis (34, 35). These conditions can lead to potentially fatal cardiac events such as stroke, myocardial infarction (heart attack), or cardiac arrest (31, 36). Thus, determining various therapeutic tools to prevent or reduce the incidence of CVD is vital.

Although cardiovascular disease can arise in response to multiple factors, the prevalence of obesity-related CVD is rapidly increasing (8). This can occur for several reasons, one being that a high fat diet or obesity can lead to hypertension. In obesity, angiotensin II and aldosterone secretion from abdominal subcutaneous adipose tissue drives activation of the renin-angiotensin system (37–41). Angiotensin II induces vasoconstriction in arterioles, causing arteriolar resistance and increased systemic blood pressure, in addition to stimulating the release of anti-diuretic hormone, which increases water reabsorption in the kidneys. Aldosterone increases the reabsorption of water and sodium into the blood, resulting in increased extracellular fluid volume, thus increasing blood pressure. The renin-angiotensin system also affects the sympathetic nervous system through inhibition of norepinephrine reuptake in the pre-synaptic sympathetic nerve terminals, increasing resting norepinephrine concentration (42), which can cause an increased resting heart rate and eventually development of hypertension (43, 44). Therefore, the renin-angiotensin system and sympathetic nervous system create a positive feedback loop to increase hypertension in obese individuals (40).

Sustained hypertension increases left ventricular afterload, forcing the left ventricle to work harder (45). This leads to pathologic hypertrophy of the ventricular walls and ventricular chamber dilation, eventually culminating in decreased myocardial function and the onset of heart failure (46, 47). As myocardial function declines, the cardiovascular system becomes impaired, resulting in insufficient blood flow. Oxygen and nutrients are then unable to meet the physiological demands of the body, resulting in tachycardia and extreme fatigue, as well as compounding health issues such as pulmonary congestion, fluid retention, and arrhythmias (48, 49).

Another potential cause of obesity-related CVD is metabolic overload of the heart, which can occur independent of hypertension. The heart is a “metabolic omnivore” (50), but in the obeseogenic state, and particularly with insulin resistance, fatty acid uptake and utilization is significantly increased (51). This can lead to inefficient β-oxidation and intramyocardial lipid accumulation (52). Because the heart has limited storage capacity, abundant accumulation of excess lipids and toxic lipid metabolites results in “lipotoxicity” which contributes to cardiac dysfunction (53–55). Indeed, several studies have demonstrated that metabolic changes precede structural changes in the heart (56, 57). Cardiac metabolism is also altered in T2D patients who are not obese. As in obesity, T2D is associated with elevated circulating free fatty acids, increased myocardial fatty acid uptake and utilization, and myocardial insulin resistance leading to decreased glucose uptake and utilization in the heart (58–61).

Atherosclerosis is the most common form of CVD, and the development of atherosclerosis progresses slowly in response to persistent exposure to an unhealthy, sedentary lifestyle, including obesity (34, 62). In an obese state, circulating levels of triglycerides and LDL cholesterol are increased (63), causing small plaques to form under endothelial cells of the innermost surface of artery walls (34, 62, 64). While normal endothelial cells can prevent adhesion of these plaques by leukocytes, under obese conditions LDL molecules are oxidized causing endothelial cells to instead express adhesion molecules and chemotactants (65–67). In response, macrophages take up oxidized LDL and are transformed into foam cells (64, 65) which localize to the fatty plaques within arteries and secrete factors that further promote plaque formation (67, 68). Resulting plaques cause vessel walls to thicken and stiffen, inhibiting blood flow (69). If the plaques become large enough or thrombosis occurs, the inhibition of blood flow can lead to ischemic conditions and cardiac events including stroke, myocardial infarction (MI), or cardiac arrest (70), all of which can be fatal.

EXERCISE TRAINING IMPROVES CARDIOVASCULAR HEALTH

There are several risk factors leading to the development and progression of CVD, but one of the most prominent is a sedentary lifestyle (34, 35, 71). A sedentary lifestyle can be characterized by both obesity and consistently low levels of physical activity. Thus, lifestyle interventions that aim to increase physical activity and decrease obesity are attractive therapeutic methods to combat most non-congenital types of CVD.

Physical Activity Decreases Cardiovascular Risk Factors

Regular physical exercise is associated with numerous health benefits to reduce the progression and development of obesity, T2D, and CVD (9–14). Several randomized clinical trials have demonstrated that lifestyle interventions including moderate exercise and a healthy diet improve cardiovascular health in at-risk populations (72, 73). Individuals with metabolic syndrome who participated in a 4 month program of either a diet (caloric restriction) or exercise intervention had reduced adiposity, decreased systolic, diastolic and mean arterial blood pressure, and lower total and low-density lipoprotein (LDL) cholesterol lipid profiles compared to the control group (12). Both the diet and exercise intervention improve these cardiovascular outcomes to a similar extent (74).

Several previous studies have investigated the effects of diet and exercise, independently or in combination, on metabolic and cardiovascular health and have determined that diet, exercise, or a combination of diet and exercise induces weight loss, decreases
visceral adiposity, lowers plasma triglycerides, plasma glucose, HDL levels, and blood pressure, and improves VO$_{2\text{max}}$ (75–78). Importantly, several of these beneficial effects of exercise are evident independent of weight loss (79). Studies have shown that exercise can improve metabolic and cardiovascular health independent of changes in body weight, including improved glucose homeostasis (80, 81), endothelial function (82), blood pressure (83), and HDL levels (84, 85). These data indicate exercise, independent of changes in body mass, results in significant improvements in cardiovascular and metabolic health. Although a detailed analysis of the vast impact of diet on cardiometabolic health is outside the scope of this review, the importance of diet and exercise in tandem should not be ignored, as many studies have shown that cardiometabolic health is improved to a higher extent in response to a combined diet and exercise programs compared to either intervention alone (86–89).

Exercise has a similar effect on cardiovascular improvements in lean and overweight normoglycemic subjects. In a 1 year study of non-obese individuals, a 16–20% increase in energy expenditure (of any form of exercise) with no diet intervention resulted in a 22.3% decrease in body fat mass and reduced LDL cholesterol, total cholesterol/HDL ratio, and C-reactive protein concentrations, all risk factors associated with CVD (74). In overweight individuals, 7–9 months of low-intensity exercise (walking ~19 km per week at 40–55% VO$_{2\text{peak}}$) significantly increased cardiorespiratory fitness compared to sedentary individuals (90). Together these data indicate that exercise interventions decrease the risk or severity of CVD in subjects who are lean, obese, or have type 2 diabetes (12, 74, 90).

**Physical Activity Improves Cardiovascular Function in Patients With CVD**

Exercise is also an important therapeutic treatment for patients who have cardiovascular diseases (14). A systematic review of 63 studies found that exercise-based cardiac rehabilitation improved cardiovascular function (91). These studies consisted of various forms of aerobic exercise at a range of intensities (from 50 to 95% VO$_{2\text{max}}$), over a multitude of time periods (1–47 months). Overall, exercise significantly reduced CVD-related mortality, decreased risk of MI, and improved quality of life (91). Another study looked specifically in patients with atherosclerosis post-revascularization surgery. Patients who underwent 60 min of exercise per day on a cycle ergometer for 4 weeks had an increase blood flow reserve (29%) and improved endothelium-dependent vasodilatation (10). A recent study provided personalized aerobic exercise rehabilitation programs for patients who had an acute myocardial infarction for 1 year after a coronary intervention surgery (92). The patients who underwent the exercise rehabilitation program had increased ejection fraction (60.81 vs. 53% control group), increased exercise tolerance, and reduced cardiovascular risk factors 6 months after starting the exercise rehabilitation program (92). This improvement in cardiovascular health in patients with atherosclerosis or post-MI is likely the result of increased myocardial perfusion in response to exercise, however more research is required to fully understand these mechanisms (10).

One defining characteristic of heart failure is exercise intolerance (93), which resulted in a prescription of bed rest for these patients until the 1950s (94). However, it has now been shown that a monitored rehabilitation program using moderate intensity exercise is safe for heart failure patients, and this has now become an important therapeutic for patients with heart failure (95–97). Meta-analyses and systemic reviews have shown that exercise training in heart failure patients is associated with improved quality of life, reduced risk of hospitalization and decreased rates of long-term mortality (93, 98–102). One study of heart failure patients found that aerobic exercise (walking or cycling) at 60–70% of heart rate reserve 3–5 times per week for over 3 years led to improved health and overall quality of life (determined by a self-reported Kansas City Cardiomyopathy Questionnaire, a 23-question disease-specific questionnaire) (103). Other studies have shown that exercise-based rehabilitation at a moderate intensity in heart failure patients improves cardiorespiratory fitness and increases both exercise endurance capacity and VO$_{2\text{max}}$ (12–31% increase) (101, 104).

More recent studies have examined the effects of high-intensity exercise on patients with heart failure. A recent study found that 12 weeks of high intensity interval training (HIIT) in heart failure patients (with reduced ejection fraction) was well-tolerated and had similar benefits compared to patients who underwent moderate continuous exercise (MCE) training, including improved left ventricular remodeling and aerobic capacity (105). A separate study found that 4 weeks of HIIT in heart failure patients with preserved ejection fraction improved VO$_{2\text{peak}}$ and reduced diastolic dysfunction compared to both pre-training values and compared to the MCE group (78). These studies indicate that both moderate and high intensity exercise training improve cardiovascular function in heart failure patients, likely related to increased endothelium-dependent vasodilation (106) and improved aerobic capacity (78, 101, 105).

**Mechanisms Regulating Exercise-Induced Benefits on Cardiovascular Health**

Multiple mechanisms mediate the benefits of regular physical exercise on cardiovascular health (13, 14) (Figure 1). Exercise represents a major challenge to whole-body homeostasis, and provokes widespread changes in numerous cells, tissues, and organs in response to the increased metabolic demand (121), including adaptations to the cardiovascular system (13, 14).

Exercise induces adaptations in several cell types and tissues throughout the body. Exercise increases mitochondrial biogenesis in adipocytes (104, 111, 112), skeletal muscle myocytes (113), and cardiomyocytes (14, 114, 115), increasing aerobic respiration within these tissues. Additionally, exercise improves oxygen delivery throughout the body through vasodilation and angiogenesis (107–110), protecting against ischemia-reperfusion injury in the heart (122, 123). Further, exercise causes a long-term anti-inflammatory effect which is inversely related to the increased inflammation typically seen in CVD and obesity.

Frontiers in Cardiovascular Medicine | www.frontiersin.org 3 June 2019 | Volume 6 | Article 69
capacity of skeletal muscle (myoglobin in skeletal muscle tissue, improving the oxidative by increasing the mitochondrial content and desaturation of exercise (107–110). Myokines released from skeletal muscle during physical exercise partially mediate these anti-inflammatory effects, and promote inter-tissue cross talk to mediate further cardiovascular benefits (117–120).

**Exercise Improves Mitochondrial Biogenesis and Function**

Many of the benefits sustained by exercise are due to mitochondrial adaptations throughout the body. For example, exercise improves long-term cardiorespiratory fitness (VO2) by increasing the mitochondrial content and desaturation of myoglobin in skeletal muscle tissue, improving the oxidative capacity of skeletal muscle (113, 124, 125). The increase of oxygen uptake and utilization by skeletal muscle (as indicated by arteriovenous oxygen difference; a-vO2) in response to regular exercise (126) is protective against a decrease in obesity-related a-vO2, resulting in individuals to require more blood to receive the same amount of oxygen (127).

Mitochondrial biogenesis is augmented in cardiomyocytes in response to exercise (14, 114, 115, 128). This is likely due to enhanced activation of AMP-activated protein kinase (AMPK) and subsequent increase mitochondrial PGC-1α expression (109, 114) Exercise also increases the ability of mitochondria to oxidize fatty acids (the predominant substrate utilized in healthy myocardium), thus increasing the capacity for ATP synthesis (14, 129–133). These exercise-induced enhancements of mitochondrial function are important in preventing cardiovascular dysfunctions often caused by obesity.

Obesity is associated with defective mitochondrial biogenesis in the myocardium (134) and reduced mitochondrial capacity for oxidative phosphorylation and ATP synthesis (135, 136). In heart failure, fatty acid uptake, and utilization is decreased (137), likely causing the heart failure associated shift toward glucose metabolism in order to preserve cardiovascular function (130, 137, 138). However, in advanced heart failure, diabetes, or obesity, myocardial insulin resistance may develop, impairing glucose uptake and accelerating cardiovascular dysfunction (139–141). Importantly, insulin sensitivity is improved in response to regular exercise (142) which is vital in reducing the risk of obesity-related insulin resistance. Insulin has also been indicated to directly regulate mitochondrial metabolism by promoting induction of OPA1, a GTPase that controls mitochondrial cristae integrity, energetics and mitochondrial DNA maintenance (143, 144), thus indicating another potential mechanism of exercise-induced improvements in cardiovascular health through mitochondrial function enhancement.

Reactive oxygen species (ROS) are physiological byproducts of aerobic mitochondrial metabolism and while necessary for initiating cellular repair or apoptosis, increased levels of ROS are associated with inflammation and several forms of CVD (145). While exercise increases the direct production of ROS by mitochondria, the net cellular ROS load is reduced by exercise due to increased action of antioxidant systems (146). Essentially, exercise creates a system in which cells exhibit a “favorable” response within low exposures of ROS, allowing antioxidant systems to work effectively (147).

By increasing the ability of mitochondria to prevent oxidative damage, exercise-induced modifications to mitochondria protect against ischemia-reperfusion damage to the heart. During ischemia, the absence of oxygen from the heart creates an environment in which the return of oxygenated blood flow leads to the induction of inflammation and oxidative stress...
rather than restoration of normal function (148). In contrast, exercise-induced adaptations to cardiomyocyte mitochondria dampen oxidative damage caused by ischemia-reperfusion, resulting in reduced cardiac injury and decreasing the risk of ischemia-related cardiac dysfunction or death (149–151).

**Exercise Improves Vasculature and Myocardial Perfusion**

Exercise training induces vascular adaptations to several tissues (107, 108). In the heart, the increase in vascularization protects against vascular stress and reduces the likelihood of a cardiac event (24–26). These adaptations are mediated through increased expression of vascular endothelial nitric oxide synthase (eNOS). Exercise increases the intensity of physiological shear stress, inducing the shear stress-dependent activity of c-Src in endothelial cells and increasing expression of eNOS (27, 152). In the vascular endothelium, eNOS catalyzes the production of nitric oxide (NO) which causes vasodilation, inhibits platelet aggregation and prevents leukocyte adhesion to vessel walls, thus reducing the onset of atherosclerosis, thrombosis, ischemia, or other cardiac events (152, 153).

Exercise also induces angiogenesis, however the mechanisms regulating this process are unclear. It has been hypothesized that the increase in nitric oxide (NO) production after exercise upregulates pro-angiogenic factors, particularly vascular endothelial growth factor (VEGF) (154). One recent study determined that male rats who underwent exercise training for 10 weeks after MI had increased Akt phosphorylation of eNOS, and reactivation of cardiac VEGF pathway activity, resulting in increased angiogenesis (155). While the mechanisms are not completely defined, it is clear that exercise induces angiogenesis, increases angiogenesis and protects against vascular stress, thus decreasing the possibility of a cardiac event (107–110, 122, 123).

**Exercise Reduces Chronic Inflammation**

Inflammation is a complex yet normal biological reaction to damaging stimuli (156). Chronic inflammation is associated with multiple diseases including obesity, T2D, and CVD (116, 157). Excess consumption of nutrients causes cells including adipocytes (158), hepatocytes (159), islet cells (160), and skeletal muscle cells (161) to activate the transcription factors nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and activator protein 1 (AP-1), increase expression of toll-like receptor 4 (TLR4) (162, 163), and stimulate the release of cytokines such as TNF-α, IL-6, IL-1β, and CCL2 (158, 164). The subsequent inflammation is modest in comparison to inflammatory responses during infection or injury (165) but remains as a chronic response to obesity termed “meta-inflammation” (163). Exercise, however, results in a long-term anti-inflammatory effect (116, 156). The exercise-induced reduction of meta-inflammation during disease is hypothesized by some to be related to downregulation of NF-κB (166–168), but exercise also decreases monocyte accumulation and suppresses the release of TNF-α and other pro-inflammatory adipokines, creating an anti-inflammatory effect (169–172).

Excess immune activation caused by obesity is of particular concern for vascular health, as activation of TLR4 causes monocyte recruitment and conversion to foam cells, driving the progression of atherosclerosis (67, 173). Exercise prevents the development of atherosclerosis by reducing expression of TLRs on monocytes and macrophages, which subsequently decreases the availability of TLR4 ligands and inhibiting pro-inflammatory cytokine production (170, 171, 174). Exercise also decreases pro-inflammatory N-terminal pro b-type natriuretic (NT-proBNP) and high-sensitivity C-reactive protein (hsCRP) within the heart, both of which are predictors of heart failure in atherosclerosis (175, 176).

**Exercise Enhances Inter-tissue Communication Through Release of Myokines**

Skeletal muscle can act as a secretory organ by stimulating the production, secretion, and expression of specific myokines after contraction (177–179). Myokines are chemical messengers that function in an autocrine, paracrine, or endocrine manner to influence crosstalk between different organs including skeletal muscle, liver, and adipose tissue (180–185). They are of great interest with regards to cardiovascular health because the well-known protective actions of exercise on cardiovascular function are at least partially mediated by increased secretion of myokines (Figure 2) (195). Some myokines that impact cardiovascular health include IL-6, myonectin, Fstl1, and NDNF (196).

**Interleukin-6 (IL-6)**

IL-6 was introduced as the first myokine over a decade ago (197). Circulating levels of IL-6 are increased in response to acute bouts of aerobic exercise (198, 199) and can act in an endocrine fashion to improve metabolic and cardiovascular health. Exercise-induced elevated concentrations of IL-6 can stimulate glucagon-like peptide-1 (GLP-1) secretion from intestinal L cells and pancreatic α cells, leading to improvements in insulin secretion and glycemia (188). IL-6 also increases lipolysis and fatty acid oxidation in adipose tissue (189) and can increase glucose uptake through stimulation of the AMP-activated protein kinase (AMPK) signaling pathway (190, 191). With regard to cardiovascular function, IL-6 can reduce inflammation by inhibiting tumor necrosis factor-α (TNF-α) (186). This results in a protective effect on cardiovascular health because TNF-α is involved in the formation of atherosclerosis, development of heart failure, and subsequent complications, including myocardial infarction (MI) (187). More investigation is required to determine the direct effects of IL-6 action on cardiovascular health.

**Myonectin**

Myonectin (or CTRP15) is abundantly expressed in skeletal muscle and is increased in response to chronic aerobic exercise (117). Importantly, injection of myonectin into wild-type mice decreases circulating free fatty acids levels by increasing fatty acid uptake in adipocytes and hepatocytes (117). Myonectin has also been identified to have protective effects on cardiovascular health; mice deficient in Myonectin had enhanced ischemic injury in response to MI while systemic delivery of myonectin attenuated ischemic injury (200). Further work is needed to
determine whether these benefits are observed in response to an increase in myonecin after exercise.

**Follistatin-Like 1 (Fstl1)**
Fstl1, also referred to as TSC-36, is a secreted glycoprotein that belongs to the follistatin family of proteins and is upregulated in skeletal muscle in response to exercise (194, 201, 202). Expression of Fstl1 is also increased in ischemic and hypertrophic hearts of mice and functions in a protective manner (118). Systemic administration of Fstl1 in both mouse and swine models led to reduced apoptosis, inflammation and injury size following ischemia-reperfusion (118, 119). In vitro, treatment of cultured cardiomyocytes with Fstl1 reduces apoptosis in response to hypoxia-reoxygenation by activating Akt and AMPK (118, 119). One recent study demonstrated that Fstl1 stimulates early fibroblast activation, which is required for acute repair and protects the heart from rupture after ischemia-reperfusion (192). While the exact role of an exercise-induced increase in Fstl1 on cardiovascular function has not been defined, these data indicate that Fstl1 is increased in response to exercise, and an increase in circulating Fstl1 functions to repair cardiovascular damage and improve cardiovascular function (202).

**Neuron-Derived Neurotrophic Factor (NDNF)**
NDNF is a glycosylated protein secreted from the endothelial cells of skeletal muscle (203). Although initially identified as a neurotrophic factor expressed in mouse brain and spinal cord (204), NDNF is also released from skeletal muscle in response to exercise (203) and acts as a hypoxia-induced pro-angiogenic factor that stimulates endothelial cell network formation through activation of the Akt/eNOS signaling pathway (194). This pro-angiogenic affect is an important component in the recovery from MI; intramuscular administration of NDNF using an adenoviral vector improved systolic function in a mouse model after MI (120). Increased NDNF levels are also associated with reduced myocardial hypertrophy and apoptosis in post-MI hearts (120). Another study showed that down-regulation of NDNF by siRNA impairs recovery from ischemia-reperfusion injury (205). Treatment of NDNF in cardiomyocytes also reduces hypoxia-induced apoptosis via activation of the focal adhesion kinase/Akt-dependent pathway (120). Additionally, increased levels of NDNF released from skeletal muscle in response to exercise enhance fatty acid oxidation through activation of AMPK (203). These data demonstrate the importance of NDNF as an endogenous ischemia- and exercise inducible factor that can enhance revascularization and therefore have a cardiovascular protective effect.

**CONCLUSIONS**
The rate of obesity-related cardiovascular disease is rapidly increasing, and often associated with additional co-morbidities including type 2 diabetes (3, 6, 8). It is clear that exercise reduces cardiovascular risk factors, and this reduction in risk factors is independent of changes to body weight or incidence of type 2 diabetes (75–77, 79, 206, 207). Exercise...
is also an important therapeutic treatment for patients who have cardiovascular diseases (14), further demonstrating the protective and restorative properties of exercise. In patients with CVD, exercise improved endothelium-dependent vasodilatation, increased ejection fraction and exercise tolerance, improved quality of life, and reduced CVD-related mortality (10, 91, 92, 101, 103, 208–211). Exercise improves cardiovascular health by several mechanisms including increased mitochondrial biogenesis and fatty acid oxidation (14, 114, 115, 128–130) dilution of blood vessels causing improved myocardial perfusion (9–11), and reduction of inflammation providing protection against the development of atherosclerosis (67, 116, 156). Myokines released from skeletal muscle during exercise also mediate systemic and cardiovascular health benefits through an anti-inflammatory action, increased fatty acid oxidation, increased glucose uptake, and improved insulin secretion and sensitivity (117, 186, 193, 196, 212–214). Importantly, several myokines (IL-6, Myonectin, Fstl1, and NDNF) have also been shown to have cardiovascular protective effects in response to ischemia–reperfusion injury (117–120, 186, 187).

While it is clear that exercise is important, the mechanistic pathways behind exercise-induced benefits on cardiovascular health are still being identified. Further understanding of the molecular mechanisms through which exercise improves cardiovascular function will lead to the development of therapeutics which can act in conjunction with exercise programs, and for individuals whom are unable or unwilling to exercise to amplify the beneficial effects of exercise.

Future research will investigate the effects of cardiac specific proteins on cardiovascular health, expanding research into the areas of system cross-talk will help delineate how other tissues, skeletal muscle in particular, can mediate cardiovascular improvements via myokine release. How these myokines affect cardiovascular function, including adaptations to mitochondrial activity, angiogenesis and inflammatory responses will provide insight into new mechanisms for the beneficial effects of exercise on cardiovascular function. Accordingly, myokines may act as potential targets for heart disease prevention and therapies. Recent studies have investigated the use of gene therapies, including the use of adeno-associated virus, on cardiovascular function. While these therapies have not been fully optimized with remaining issues in immunogenicity, efficacy and genotoxicity (215), their development provides excitement for the potential therapies focused on exercise-induced myokines that improve cardiovascular function as a treatment for patients who are unable, or perhaps unwilling, to exercise. Together these data highlight the importance of exercise and exercise-related therapies to both prevents the development of cardiovascular disease and promotes recovery and improved health in patients with CVD.

AUTHOR CONTRIBUTIONS

KP, KKB, and KIS outlined, drafted, and contributed to the writing of the manuscript. All authors approved the final version of the manuscript.

FUNDING

This work was supported by National Institutes of Health Grants R01-HL138738 and 17CSA33610078 to KIS and K01-DK116916 to KKB.

REFERENCES

1. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of Obesity Among Adults and Youth: United States, 2015–2016. U.S. Department of Health and Human Services; National Center for Health Statistics; Centers for Disease Control and Prevention (2017).
2. Brown CD, Higgins M, Donato KA, Rohde FC, Garrison R, Obarzanek E, et al. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res. (2000) 8:605–19. doi: 10.1038/oby.2000.79
3. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. (2009) 9:88. doi: 10.1186/1471-2458-9-88
4. LamontFava S, Wilson PWF, Schaefer EJ. Impact of body mass index on coronary heart disease risk factors in men and women - The Framingham Offspring Study. Arterioscl Throm Vas. (1996) 16:1509–15. doi: 10.1161/01.ATV.16.12.1509
5. Wilson PWF, D’Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk - The Framingham experience. Arch Intern Med. (2002) 162:1867–72. doi: 10.1001/archinte.162.16.1867
6. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. (2006) 444:875–80. doi: 10.1038/nature05487
7. Moore JX, Chaudhary N, Akinremiyo T. Metabolic syndrome prevalence by race/ethnicity and sex in the united states. national health and nutrition examination survey, 1988-2012. Prev Chronic Dis. (2017) 14:160287. doi: 10.5888/pcd14.160287
8. Kivimaki M, Kuosma E, Ferrie JE, Luukkonen R, Nyberg ST, Alfredsson L, et al. Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120 813 adults from 16 cohort studies from the USA and Europe. Lancet Public Health. (2017) 2:e277–85. doi: 10.1016/S2468-2667(17)30074-9
9. Ashor AW, Lara J, Sierro M, Celis-Morales C, Oggioni C, Jakovljevic DG, et al. Exercise modalities and endothelial function: a systematic review and dose-response meta-analysis of randomized controlled trials. Sports Med. (2015) 45:279–96. doi: 10.1007/s40279-014-0272-9
10. Hambrecht R, Wolf A, Gielen S, Linke A, Hofer J, Erbs S, et al. Effect of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med. (2000) 342:454–60. doi: 10.1056/NEJM200002173420702
11. Laughlin MH, Bowles DK, Duncker DJ. The coronary circulation in exercise training. Am J Physiol-Heart C. (2012) 302:H10–23. doi: 10.1152/ajpheart.00574.2011
12. Pettman TL, Buckley JD, Misan GM, Coates AM, Howe PR. Health benefits of a 4-month group-based diet and lifestyle modification program for individuals with metabolic syndrome. Obes Res Clin Pract. (2009) 3:221–35. doi: 10.1016/j.orcp.2009.06.002
13. Platt C, Houstis N, Rosenzweig A. Using exercise to measure and modify cardiac function. Cell Metab. (2015) 21:227–36. doi: 10.1016/j.cmet.2015.01.014
14. Vega RB, Konhilas JP, Kelly DP, Leinwand LA. Molecular mechanisms underlying cardiac adaptation to exercise. Cell Metab. (2017) 25:1012–26. doi: 10.1016/j.cmet.2017.04.025
15. Che L, Li D. The effects of exercise on cardiovascular biomarkers: new Insights, recent data, and applications. Adv Exp Med Biol. (2017) 999:43–53. doi: 10.1007/978-981-10-4307-9_3

Frontiers in Cardiovascular Medicine | www.frontiersin.org 7 June 2019 | Volume 6 | Article 69
16. Stanford KI, Goodyear LJ. Exercise and type 2 diabetes: molecular mechanisms regulating glucose uptake in skeletal muscle. Adv Physiol Educ. (2014) 38:308–14. doi: 10.1152/advan.00080.2014

17. Nystoriak MA, Bhatnagar A. Cardiovascular Effects and Benefits of Exercise. Front Cardiovasc Med. (2018) 5:135. doi: 10.3389/fcmv.2018.00135

18. Egan B, Zierath JR. Exercise metabolism and the molecular regulation of skeletal muscle adaptation. Cell Metab. (2013) 17:162–84. doi: 10.1016/j.cmet.2012.12.012

19. Slentz CA, Bateman LA, Willis LH, Granville EO, Piner LW, Samsa GP, et al. Effects of exercise training alone vs. a combined exercise and nutritional lifestyle intervention on glucose homeostasis in prediabetic individuals: a randomised controlled trial. Diabetologia. (2016) 59:2088–98. doi: 10.1007/s00125-016-4051-z

20. Conn VS, Koopman RJ, Ruppap TM, Phillips LJ, Mehr DR, Hafsah AR. Insulin sensitivity following exercise interventions: systematic review and meta-analysis of outcomes among healthy adults. J Prim Care Community Health. (2014) 5:211–22. doi: 10.1177/2151319113520328

21. Lin X, Zhang X, Guo J, Roberts CK, McKenzie S, Wu WC, et al. Effects of exercise training on cardiorespiratory fitness and biomarkers of cardiometabolic health: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. (2015) 4:e002014. doi: 10.1161/JAHA.115.002014

22. Ruderman NB, Park H, Kaushik VK, Dean D, Constanti S, Prentki M, et al. AMPK as a metabolic switch in rat muscle, liver and adipose tissue after exercise. Acta Physiol Scand. (2003) 178:435–42. doi: 10.1046/j.1365-201X.2003.00164.x

23. Petridou A, Nikolaidis MG, Matsakas A, Schulz T, Michna H, Mougios V. Effect of exercise training on the fatty acid composition of lipid classes in rat liver, skeletal muscle, and adipose tissue. Eur J Appl Physiol. (2005) 94:84–92. doi: 10.1007/s00421-004-1294-z

24. Hambrecht R, Adams V, Erbs S, Linke A, Kranke N, Shu Y, et al. Regular physical activity improves endothelial function in patients with coronary artery disease by increasing phosphorylation of endothelial nitric oxide synthase. Circulation. (2003) 107:3152–8. doi: 10.1161/01.CIR.0000074229.93804.SC

25. Leung FP, Yung LM, Laher I, Yao XQ, Chen ZY, Huang Y. Exercise, vascular wall and cardiovascular diseases an update (Part 1). Sports Med. (2008) 38:1099–24. doi: 10.2165/00007256-200838120-00005

26. Fiuzza-Luces C, Garatache N, Berger NA, Lucia A. Exercise is the real polypill. Physiology. (2013) 28:330–58. doi: 10.1152/physiology.00019.2013

27. Davis ME, Cai H, McCann L, Fukai T, Harrison DG. Role of c-Src in regulation of endothelial nitric oxide synthase expression during exercise training. Am J Physiol-Heart Circ. (2003) 284:H1449–53. doi: 10.1152/ajpheart.00918.2002

28. Ellison GM, Waring CD, Vicinanza C, Torella D. Physiological analysis of randomized controlled trials. J Physiol. (2005) 94:84–92. doi: 10.1113/jphysiol.2004.072893

29. Leung FP, Yung LM, Laher I, Yao XQ, Chen ZY, Huang Y. Exercise, vascular wall and cardiovascular diseases an update (Part 1). Sports Med. (2008) 38:1099–24. doi: 10.2165/00007256-200838120-00005

30. Fiuzza-Luces C, Garatache N, Berger NA, Lucia A. Exercise is the real polypill. Physiology. (2013) 28:330–58. doi: 10.1152/physiology.00019.2013

31. Ruderman NB, Park H, Kaushik VK, Dean D, Constanti S, Prentki M, et al. AMPK as a metabolic switch in rat muscle, liver and adipose tissue after exercise. Acta Physiol Scand. (2003) 178:435–42. doi: 10.1046/j.1365-201X.2003.00164.x

32. Petridou A, Nikolaidis MG, Matsakas A, Schulz T, Michna H, Mougios V. Effect of exercise training on the fatty acid composition of lipid classes in rat liver, skeletal muscle, and adipose tissue. Eur J Appl Physiol. (2005) 94:84–92. doi: 10.1007/s00421-004-1294-z

33. Hambrecht R, Adams V, Erbs S, Linke A, Kranke N, Shu Y, et al. Regular physical activity improves endothelial function in patients with coronary artery disease by increasing phosphorylation of endothelial nitric oxide synthase. Circulation. (2003) 107:3152–8. doi: 10.1161/01.CIR.0000074229.93804.SC

34. Leung FP, Yung LM, Laher I, Yao XQ, Chen ZY, Huang Y. Exercise, vascular wall and cardiovascular diseases an update (Part 1). Sports Med. (2008) 38:1099–24. doi: 10.2165/00007256-200838120-00005

35. Fiuzza-Luces C, Garatache N, Berger NA, Lucia A. Exercise is the real polypill. Physiology. (2013) 28:330–58. doi: 10.1152/physiology.00019.2013
Exercise Improves Cardiovascular Health

Pinckard et al.  Exercise Improves Cardiovascular Health

58. Lopaschuk GD, Ussher JR, Holmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. *Physiol. Rev.* (2010) 90:207–58. doi: 10.1152/physrev.00015.2009

59. Taegtmeyer H, McNulty P, Young ME. Adaptation and maladaptation of the heart in diabetes: part I: general concepts. *Circulation.* (2002) 105:1727–33. doi: 10.1161/01.CIR.000002467.61045.87

60. Young ME, McNulty P, Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes: part II: potential mechanisms. *Circulation.* (2002) 105:1861–70. doi: 10.1161/01.CIR.000002467.61045.87

61. Brahma MK, Pepin ME, Wende AR. My sweetheart is broken: role of glucose in diabetic cardiomyopathy. *Diabetes Metab J.* (2017) 41:1–9. doi: 10.4093/dmj.2017.41.1.1

62. Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. *Nat Rev Cardiol.* (2009) 6:399–409. doi: 10.1038/nrcardio.2009.55

63. Klop B, Elte JW, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. *Nutrients.* (2013) 5:1218–40. doi: 10.3390/nu5041218

64. Teodori L, Mallat Z. [Atherosclerotic plaque formation]. *Rev Prat.* (1999) 49:2081–6.

65. Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. *Circ. Res.* (2014) 114:1852–66. doi: 10.1161/CIRCRESAHA.114.302721

66. Libby P. Inflammation and cardiovascular disease mechanisms. *Am J Clin Nutr.* (2006) 83:456–60. doi: 10.1093/ajcn/83.2.4565

67. Yusuf S, Lopez SR, Tubau F, Zenere S, Marro J, Hawken S, et al. Obesity and the risk of coronary heart disease, stroke, and type 2 diabetes: a pooled analysis of 97 prospective studies. *Lancet.* (2010) 376:1741–50. doi: 10.1016/S0140-6736(10)61462-8

68. Bobryshev YV, Ivanova EA, Chistiakov DA, Nikiforov NG, Orekhov AN. Macrophages and their role in atherosclerosis: pathophysiology and transcriptome analysis. *Biomed Res Int.* (2016). doi: 10.1155/2016/9582430.

69. Patzelt J, Verschoor A, Langer HF. Platelets and the complement cascade in plaque formation and rupture. *Front. Physiol.* (2015) 6:69. doi: 10.3389/fphys.2015.00049

70. Thygesen K, Alpert JS, Jaffe AS, Ma/memory ML, Chaitman BR, et al. Myocardial infarction: a universal definition. *J Am Coll Cardiol.* (2007) 105:1861–70. doi: 10.1161/01.CIR.000002467.61045.87

71. Young DR, Hivert MF, Alhassan S, Camhi SM, Ferguson JF, Katzmarzyk PT, et al. Sedentary behavior and cardiovascular morbidity and mortality: a science advisory from the american heart association. *Circulation.* (2016) 134:e262–79. doi: 10.1161/CIR.0000000000000440

72. Miele EM, S. Headley AE. The effects of chronic aerobic exercise on fatty acid metabolism in health and disease. *Nutrients.* (2016) 8(3):456. doi: 10.3390/nu803005604

73. Drenowatz C, S. Headley AE. The effects of chronic aerobic exercise on fatty acid metabolism in health and disease. *Circulation.* (2016) 134:e262–79. doi: 10.1161/CIR.0000000000000440

74. Miele EM, S. Headley AE. The effects of chronic aerobic exercise on fatty acid metabolism in health and disease. *Circulation.* (2016) 134:e262–79. doi: 10.1161/CIR.0000000000000440

75. Wing RR, Lang W, Wadden TA, Safford M, Kowler WC, Bertoni AG, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. *Diabetes Care.* (2011) 34:1481–6. doi: 10.2337/dc10-2415

76. Dandanell S, Skovborg C, Praest CB, Kristensen KB, Nielsen MG, Lionett S, et al. The effects of exercise training on plaque formation and rupture. *Front. Physiol.* (2013) 4:540–7. doi: 10.3389/fphys.2013.00049

77. Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. *Lancet.* (2018) 391:541–51. doi: 10.1016/S0140-6736(17)33102-1

78. Angadi SS, Mookadam F, Lee CD, Tucker WJ, Haykowsky MJ, Gaesser GA. High-intensity interval training vs. moderate-intensity continuous exercise training in heart failure with preserved ejection fraction: a pilot study. *J Appl Physiol.* (2015) 119:753–8. doi: 10.1152/japplphysiol.00518.2014

79. Gaesser GA, Angadi SS, Sawyer BJ. Exercise and diet, independent of weight loss, improve cardiometabolic risk profile in overweight and obese individuals. *Physician Sportsmed.* (2011) 39:87–97. doi: 10.1080/10764294.2011.1051899
Exercising improves cardiovascular health

98. Piepoli MF, Davos C, Francis DP, Coats AJ, ExTra MC. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ. (2004) 328:189. doi: 10.1136/bmj.37938.645220.EE

99. Davies El, Moxham T, Rees K, Singh S, Coats AJ, Ellaham S, et al. Exercise training for systolic heart failure: cochrane systematic review and meta-analysis. Eur J Heart Fail. (2010) 12:706–15. doi: 10.1038/ejhfph056

100. Sagar VA, Davies El, Briscoe S, Coats Al, Dalal HM, Lough E, et al. Exercise-based rehabilitation for heart failure: systematic review and meta-analysis. Open Heart. (2015) 2:e000163. doi: 10.1136/openheart-2014-000163

101. Taylor RS, Sagar VA, Davies El, Briscoe S, Coats Al, Dalal H, et al. Exercise-based rehabilitation for heart failure. Cochrane Database Syst Rev. (2014) 4:CD003331. doi: 10.1002/14651858.CD003331.pub4

102. O’Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, et al. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. (2009) 301:1439–50. doi: 10.1001/jama.2009.454

103. Flynn KE, Pina IL, Whellan DJ, Lin L, Blumenthal JA, Ellis SJ, et al. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. (2009) 301:1451–9. doi: 10.1001/jama.2009.457

104. Asrar Ul Haq M, Goh CY, Levering I, Wong C, Hare DL. Clinical utility of exercise training in heart failure with reduced and preserved ejection fraction. Clin Med Insights Cardiol. (2015) 9:1–9. doi: 10.4155/cmc.2015.127

105. Ellingsen O, Halle M, Conraads VM, Stoylen A, Dalen H, Delagardelle C, et al. High-intensity interval training in patients with heart failure with reduced ejection fraction. Circulation. (2017) 135:839–49. doi: 10.1161/CIRCULATIONAHA.116.022924

106. Pearson MJ, Smart NA. Effect of exercise training on endothelial function in heart failure patients: a systematic review meta-analysis. Int J Cardiol. (2017) 231:234–43. doi: 10.1016/j.ijcard.2016.12.145

107. Hoier B, Hellsten Y. Exercise-induced capillary growth in human skeletal muscle, and the brain. Prog Mol Biol Transl Sci. (2015) 135:227–57. doi: 10.1016/b978-0-12-805166-0.00008-6

108. Tao L, Bei Y, Zhang H, Xiao J, Li X. Exercise for the heart: signaling pathways. J Am Coll Cardiol. (2016) 68:CD003331. doi: 10.1002/14651858.CD003331.pub4

109. Black MA, Cable NT, Thijssen DH, Green DJ. Impact of age, sex, and exercise training-induced changes in vascular structure and function: skeletal muscle, cardiac muscle, and the brain. Circ Res. (2015) 117:3099–108. doi: 10.1161/CIRCULATIONAHA.108.767673

110. Ogura Y, Ouchi N, Ohashi K, Shibata R, Kataoka Y, Kambara T, et al. Therapeutic impact of follistatin-like 1 on myocardial ischemic injury in preclinical models. Circulation. (2012) 126:1728–38. doi: 10.1161/CIRCULATIONAHA.112.115089

111. Joki Y, Ohashi K, Yuasa D, Shibata R, Kataoka Y, Kambara T, et al. Neuron-derived neurotrophic factor ameliorates adverse cardiac remodeling after experimental myocardial infarction. Circ Heart Fail. (2015) 8:342–51. doi: 10.1161/CIRCHEARTFAILURE.114.001647

112. Hawley JA, Hargreaves M, Joyner MJ, Zierath JR. Integrative biology of exercise. Cell. (2014) 159:738–49. doi: 10.1016/j.cell.2014.10.029

113. Borges JP, da Silva Verdoorn K. Cardiac ischemia/reperfusion injury: the beneficial effects of exercise. Adv Exp Med Biol. (2017) 999:155–179. doi: 10.1007/978-981-10-4307-9_10

114. Sattelmair J, Pertman I, Ding EL, Kohl HW, III, Haskell W, Lee JM. Dose response between physical activity and risk of coronary heart disease: a meta-analysis. Circulation. (2011) 124:789–95. doi: 10.1161/CIRCULATIONAHA.110.010710

115. Irving BA, Lanza IR, Henderson GC, Rao RR, Spiegelman BM, Nair KS. Combined training enhances skeletal muscle mitochondrial oxidative capacity independent of age. J Clin Endocrinol Metab. (2015) 100:1654–63. doi: 10.1210/jc.2014-3081

116. Konopka AR, Suer MK, Wolf CA, Harber MP. Markers of human skeletal muscle mitochondrial biogenesis and quality control: effects of age and aerobic exercise training. J Gerontol A Biol Sci Med Sci. (2014) 69:371–8. doi: 10.1093/gerona/glt107

117. Glynn A, Fiddler H. Introduction to Exercise Physiology. In: Chambers G, editor. The Physiotherapist’s Pocket Guide to Exercise Assessment, Prescription and Training. London: Churchill Livingstone (2009).

118. Vella CA, Ontiveros D, Zubia RY. Cardiac function and arteriovenous oxygen difference during exercise in obese adults. Eur J Appl Physiol. (2011) 112:915–23. doi: 10.1007/s00421-010-1554-x

119. Judge S, Jang YM, Smith A, Selman C, Phillips T, Speaman JR, et al. Exercise by lifelong voluntary wheel running reduces subsarcolemmal and interfibrillar mitochondrial hydrogen peroxide production in the heart. Am J Physiol-Reg I. (2005) 289:R1564–72. doi: 10.1152/ajpregu.00396.2005

120. Dufour CR, Wilson BJ, Huss JM, Kelly DP, Alaynick WA, Downes M, et al. Genome-wide orchestration of cardiac functions by the orphan nuclear receptors ERRalpha and gamma. Cell Metab. (2007) 5:345–56. doi: 10.1016/j.cmet.2007.03.007

121. Tao L, Bei Y, Lin S, Zhang H, Zhou Y, Jiang J, et al. Exercise training protects against acute cardiac myocardial infarction via improving myocardial energy metabolism and mitochondrial biogenesis. Cell Physiol Biochem. (2015) 37:162–75. doi: 10.1007/s00973-015-3034-z

122. Ferreira R, Nogueira-Ferreira R, Trindade F, Vitorino R, Powers SK, Moreira-Goncalves D, Sugar or fat: the metabolic choice of the trained heart. Metabolism. (2018) 87:98–104. doi: 10.1016/j.metabol.2018.07.004

123. Kolwicz SC, Jr. An exercise in cardiac metabolism. Front Cardiovasc Med. (2018) 5:66. doi: 10.3389/fcvm.2018.00066

124. Burelle Y, Wambolt RB, Grist M, Parsons HL, Chow JC, Antler C, et al. Therapeutic impact of follistatin-like 1 on myocardial ischemic injury in preclinical models. Circ Res. (2012) 110:255–64. doi: 10.1161/CIRCRESAHA.111.300376

125. Casademont J, Miro O. Electron transport chain defects in heart failure. Heart Fail Rev. (2002) 7:131–9. doi: 10.1023/A:1015372407647

126. Neubauer S. The failing heart—an engine out of fuel. N Engl J Med. (2007) 356:1140–51. doi: 10.1056/NEJMra060352

127. Docherty JT, Nguyen TD, Abel ED. Cardiac metabolism in heart failure: implications beyond ATP production. Circ Res. (2013) 113:709–24. doi: 10.1161/CIRCRESAHA.113.300376

128. Rosenblatt-Velin N, Montessuit C, Papageorgiou I, Terrand J, Lerc H. Postinfarction heart failure in rats is associated with upregulation of GLUT-1 and that is secreted by the heart. Circulation. (2008) 117:3099–108. doi: 10.1161/CIRCULATIONAHA.108.767673

129. O’Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, et al. Exercise training for heart failure: HF-ACTION randomized controlled trial. JAMA. (2009) 301:1439–50. doi: 10.1001/jama.2009.454

130. Taylor RS, Sagar VA, Davies El, Briscoe S, Coats Al, Dalal H, et al. Exercise-based rehabilitation for heart failure. Cochrane Database Syst Rev. (2014) 4:CD003331. doi: 10.1002/14651858.CD003331.pub4
and downregulation of genes of fatty acid metabolism. *Cardiovasc Res.* (2001) 52:407–16. doi: 10.1016/S0008-6363(01)00393-5

139. Velez M, Kohli S, Sabbah HN. Animal models of insulin resistance and heart failure. *Heart Fail Rev.* (2014) 19:1–13. doi: 10.1007/s10741-013-9387-6

140. Ashrafian H, Frenneaux MP, Opie LH. Metabolic mechanisms in heart failure. *Circulation.* (2007) 116:434–48. doi: 10.1161/CIRCULATIONAHA.107.702795

141. Abel ED, O’Shea KM, Ramasamy R. Insulin resistance: metabolic mechanisms and consequences in the heart. *Arterioscler Thromb Vasc Biol.* (2012) 32:2068–76. doi: 10.1161/ATVBAHA.111.241984

142. Bloomer RJ, Goldfarb AH, Wideman L, McKenzie MJ, Consitt LA. Effects of physical activity on ischemia-reperfusion injury. *Arterioscler Thromb Vasc Biol.* (2005) 25:376–85. doi: 10.1161/01.ATV.0000184631.07375.98

143. Bird SR, Hawley JA. Update on the effects of physical activity on insulin resistance in humans. *BMJ Open Sport Exerc Med.* (2016) 2:e000143. doi: 10.1136/bmjsem-2016-000143

144. Incalza MA, D’Oria R, Natalicchio A, Perrini S, Laviola L, Giorgino F. Insulin signaling and heart failure. *Circ Res.* (2012) 110:1831–42. doi: 10.1161/CIRCRESAHA.111.295790

145. Parra V, Verdejo HE, Iglewski M, Del Campo A, Troncoso R, Jones D, et al. Insulin stimulates mitochondrial fusion and function in cardiomyocytes via the Akt-mTOR-NF-kappaB-Op1 signaling pathway. *Diabetes.* (2016) 65:73–85. doi: 10.2337/db13-0340

146. Riehle C, Abel ED. Insulin signaling and heart failure. *Circ Res.* (2016) 118:1151–69. doi: 10.1161/CIRCRESAHA.116.306206

147. Prior BM, Yang HT, Terjung RL. What makes vessels grow? *Int Rev Cell Mol Biol.* (2005) 233:109–53. doi: 10.1016/B978-0-12-394309-5.00006-7

148. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. *Circ Res.* (2005) 96:939–49. doi: 10.1161/01.RES.0000163655.62973.34

149. Calo E, Frühbeck G. Inflammation and the resolving microbiome. *Nature.* (2014) 510:311–5. doi: 10.1038/510311a

150. Menke D, Hoffmann C, Weigt C. Skeletal muscle as an endocrine organ: the role of myokines in exercise adaptations. *Cold Spring Harb Perspect Med.* (2017) 7:a029793. doi: 10.1101/cshperspect.a029793
human skeletal muscle cells. Arch Physiol Biochem. (2013) 119:75–80. doi:10.3109/13813455.2013.768270

20. Xi Y, Gong DW, Tian ZJ. FSTL1 as a Potential mediator of exercise-induced cardioprotection in post-myocardial infarction rats. Sci Rep. (2016) 6:32424. doi:10.1038/srep32424

21. Matthews VB, Aström MB, Chan MHS, Bruce CR, Krabble KS, Prelovec O, et al. Brain-derived neurotrophic factor is produced by skeletal muscle cells in response to contraction and enhances fat oxidation via activation of AMP-activated protein kinase. Diabetologia. (2009) 52:1409–18. doi:10.1007/s00125-009-1364-1

22. Kuang XL, Zhao XM, Xu HF, Shi YY, Deng JB, Sun GT. Spatio-temporal expression of a novel neuron-derived neurotrophic factor (NDNF) in mouse brains during development. BMC Neurosci. (2010) 11:137. doi:10.1186/1471-2202-11-137

23. Ohashi K, Enomoto T, Ioki Y, Shibata R, Ogura Y, Katoaka Y, et al. Neuron-derived neurotrophic factor functions as a novel modulator that enhances endothelial cell function and revascularization processes. J Biol Chem. (2014) 80:1413–42. doi:10.1074/jbc.M114.555789

24. Pandey A, Suskin N, Poirier P. The impact of burst exercise on cardiometabolic status of patients newly diagnosed with type 2 diabetes. Can J Cardiol. (2017) 33:1645–51. doi:10.1016/j.cjca.2017.09.019

25. Chudyk A, Petrella RJ. Effects of exercise on cardiovascular risk factors in type 2 diabetes: a meta-analysis. Diabetes Care. (2011) 34:1228–37. doi:10.2337/dc10-1058

26. Meyer K, Schwaibl M, Westbrook S, Beneke R, Hajric R, Gornandi L, et al. Effects of short-term exercise training and activity restriction on functional capacity in patients with severe chronic congestive heart failure. Am J Cardiol. (1996) 78:1017–22. doi:10.1016/0002-9149(96)00527-9

27. Maiorana A, O’Driscoll G, Cheetham C, Collis J, Goodman C, Rankin S, et al. Combined aerobic and resistance exercise training improves functional capacity and strength in CHF. J Appl Physiol. (2000) 88:1565–70. doi:10.1152/jappl.2000.88.5.1567

28. Pena LL, Apstein CS, Balady GJ, Belardinelli R, Chaitman BR, Duschà BD, et al. Exercise and heart failure – A statement from the American Heart Association Committee on Exercise, Rehabilitation, and Prevention. Circulation. (2003) 107:1210–25. doi:10.1161/01.CIR.0000055013.92097.40

29. Maugeri FS, Campana M, Ferrari R, Giordano A, Scalvini S,Voltterra M, et al. Experience from controlled trials of physical training in chronic heart failure - Protocol and patient factors in effectiveness in the improvement in exercise tolerance. Eur Heart J. (1998) 19:466–473. doi:10.1053/euhj.1997.0736

30. Busquets S, Figueras M, Almendro V, Lopez-Soriano FJ, Argiles JM. Interleukin-15 increases glucose uptake in skeletal muscle. An antiadipogenic effect of the cytokine. Biochem Biophys Res Commun. (2004) 320:449–54. doi:10.1016/j.bbrc.2004.05.188

31. Carey AL, Steinberg GR, Macaulay SL, Thomas WG, Holmes AG, Ramm G, et al. Interleukin-6 stimulates insulin secretion in human skeletal muscle cells. Arch Physiol Biochem. (2003) 88:3005–10. doi:10.1016/S0012-9380(02)021687

32. Kelly M, Keller C, Avilucea PR, Keller P, Luo Z, Xiang X, et al. AMPK activity is diminished in tissues of IL-6 knockout mice: the effect of exercise. Biochem Biophys Res Commun. (2004) 320:449–54. doi:10.1016/j.bbrc.2004.05.188

33. Carey AL, Steinberg GR, Macaulay SL, Thomas WG, Holmes AG, Ramm G, et al. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes. (2006) 55:2688–97. doi:10.2337/db05-1404

34. Maruyama S, Nakamura K, Papanicolaou KN, Sano S, Shimizu I, Asaumi Y, et al. Follistatin-like-1 promotes cardiac fibroblast activation and protects the heart from rupture. EMBO Mol Med. (2016) 8:949–66. doi:10.15252/emmm.201506151

35. Otaka N, Shibata R, Ohashi K, Uemura Y, Kambara T, Enomoto T, et al. Myostatin is an exercise-induced myokine that protects the heart from ischemia-reperfusion injury. Circ Res. (2012) 113:1513–23. doi:10.1161/circresaha.111.101777

36. Ouchi N, Ohashi K, Shibata R, Murohara T. Protective roles of adipokines and myokines in cardiovascular disease. Circ J. (2016) 80:2073–80. doi:10.1253/circj.CJ-16-0663

37. Pedersen BK, Fischer CP. Beneficial health effects of exercise - the role of IL-6 as a myokine. Trends Pharmacol Sci. (2007) 28:152–6. doi:10.1016/j.tips.2007.02.002

38. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. (2012) 8:457–65. doi:10.1038/nrendo.2012.49

39. Mathur N, Pedersen BK. Exercise as a mean to control the systemic relevance? Mediat Inflamm. (2008) 2008:109502. doi:10.1155/2008/109502

40. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev. (2008) 88:1379–406. doi:10.1152/physrev.00100.2007

41. Fischer CP. Interleukin-6 in acute exercise and training: what is the biological relevance? Exerc Immunol Rev. (2006) 12:6–33

42. Yuasa D, Ohashi K, Shibata R, Mizutani N, Katoaka Y, Kambara T, et al. C1q/TNF-related protein-1 functions to protect against acute ischemic injury. Faseb J. (2016) 30:1065–75. doi:10.1096/fj.15-279885

43. Gorgens SW, Raschke S, Holven KB, Jensen J, Eckardt K, Eckel J. Regulation of follistatin-like protein 1 expression and secretion in primary